Charles River Laboratories CRL Inventory, step-up amortization

Inventory, step-up amortization at other companies

Medline, Inc. MDLN

$0-100%

AmcorAMCR

$33.25M—

Boston ScientificBSX

$2M-97.5%

Medline, Inc. MDLN

$0-100%

Viavi Solutions Inc.VIAV

$900K-47.1%

BiogenBIIB

$107.6M+109%

Other financials

Income statement

See full

Revenue$995.8M+1.2%

Gross profit$349.0M-3.5%

Operating income$119.9M+60.6%

Net income-$14.8M-158%

EPS (diluted)-$0.30-160%

Balance sheet

See full

Cash & equivalents$198.2M-14.5%

Total debt$3.1B+1.9%

Total equity$2.9B-7.9%

Total assets$7.7B+2.0%

Cash flow

See full

Operating cash flow$41.1M-76.1%

CapEx$55.9M-5.8%

Free cash flow-$14.8M-113%

Valuation

See full

Market cap$8.91B+10.3%

Enterprise value$11.79B+8.5%

P/S2.2×+0.2×

Profitability

See full

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-4.6%—

FCF margin9.7%-4.3pp

Returns & leverage

See full

Return on equity-6%—

Debt / equity1×+0.1×

Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept crl:InventoryStepUpAmortization.

The official record: Charles River Laboratories’s 10-K, filed February 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's inventory, step-up amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Charles River Laboratories's inventory, step-up amortization?: Charles River Laboratories (CRL) reported inventory, step-up amortization of $6.13M in Q4 2025.
How has Charles River Laboratories's inventory, step-up amortization changed year-over-year?: Charles River Laboratories's inventory, step-up amortization decreased by 11.6% year-over-year, from $6.93M to $6.13M.